Company intelligence / Profile preview

Repros Therapeutics Inc.

The Woodlands, Texas, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Phase 3

Overview

The company developed drug candidates including Proellex and Androxal (enclomiphene). Enclomiphene received a Complete Response Letter from the FDA in 2015. None of their products received FDA approval as of 2017 when the company was acquired.

Therapeutic areas: Men's HealthWomen's Health
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

4 assets

ImmuMax

Pre-clinical

Indications: Adjuvant

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Repros Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Repros Therapeutics Inc..

Explore the full profile